All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (Current) smoker (Former) smoker (never) stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mNSCLC - L1 - PDL1 positive, anti-PD-(L)1 vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 026 (PDL1>1%), 2016 1.07 [0.86; 1.33]
CheckMate 026 (PDL1>5%), 2016 1.02 [0.80; 1.30]
EMPOWER lung1 (PDL1>50%), 2021 0.57 [0.42; 0.77]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.83 [0.65; 1.06]
IMpower-110 (TC2/3 or IC2/3), 2020 0.72 [0.52; 0.99]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.40; 0.88]
KEYNOTE-024 (PDL1>50%), 2016 0.60 [0.41; 0.88]
KEYNOTE-042 (PDL1>1%), 2019 0.81 [0.71; 0.93]
KEYNOTE-042 (PDL1>20%), 2019 0.77 [0.64; 0.92]
KEYNOTE-042 (PDL1>50%), 2019 0.69 [0.56; 0.85]
MYSTIC (D ; PDL1>25%), 2020 0.76 [0.56; 1.03]
0.78 [0.69 ; 0.87 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, MYSTIC (D ; PDL1>25%), 2020 11 56% 5,935 moderate low deaths (OS) (extension)detailed results IMpower-110 (TC3 or IC3), 2020 0.76 [0.53; 1.08]
KEYNOTE-024 (PDL1>50%), 2016 0.62 [0.48; 0.81]
KEYNOTE-042 (PDL1>1%), 2019 0.80 [0.71; 0.90]
KEYNOTE-042 (PDL1>20%), 2019 0.75 [0.64; 0.88]
KEYNOTE-042 (PDL1>50%), 2019 0.98 [0.82; 1.18]
0.79 [0.69 ; 0.90 ] IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019 5 56% 3,201 moderate not evaluable PFS (extension)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.72 [0.60; 0.86]
IMpower-110 (TC2/3 or IC2/3), 2020 0.64 [0.50; 0.82]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.43; 0.81]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.39; 0.65]
KEYNOTE-042 (PDL1>1%), 2019 1.05 [0.93; 1.18]
KEYNOTE-042 (PDL1>20%), 2019 0.95 [0.82; 1.10]
KEYNOTE-042 (PDL1>50%), 2019 0.85 [0.71; 1.01]
0.75 [0.62 ; 0.91 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019 7 86% 4,083 moderate serious progression or deaths (PFS)detailed results CheckMate 026 (PDL1>1%), 2016 1.17 [0.95; 1.44]
CheckMate 026 (PDL1>5%), 2016 1.15 [0.91; 1.45]
EMPOWER lung1 (PDL1>50%), 2021 0.54 [0.43; 0.68]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.77 [0.63; 0.94]
IMpower-110 (TC2/3 or IC2/3), 2020 0.67 [0.52; 0.87]
IMpower-110 (TC3 or IC3), 2020 0.63 [0.45; 0.88]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.37; 0.68]
KEYNOTE-042 (PDL1>1%), 2019 1.07 [0.94; 1.21]
KEYNOTE-042 (PDL1>20%), 2019 0.94 [0.80; 1.11]
KEYNOTE-042 (PDL1>50%), 2019 0.81 [0.67; 0.98]
MYSTIC (D ; PDL1>25%), 2020 0.87 [0.59; 1.29]
0.81 [0.69 ; 0.96 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, MYSTIC (D ; PDL1>25%), 2020 11 84% 5,935 moderate critical objective responses (ORR)detailed results CheckMate 026 (PDL1>5%), 2016 0.70 [0.46; 1.06]
EMPOWER lung1 (PDL1>50%), 2021 2.53 [1.32; 4.85]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.89 [0.62; 1.27]
IMpower-110 (TC2/3 or IC2/3), 2020 0.94 [0.59; 1.50]
IMpower-110 (TC3 or IC3), 2020 1.55 [0.86; 2.79]
KEYNOTE-024 (PDL1>50%), 2016 2.11 [1.31; 3.39]
KEYNOTE-042 (PDL1>1%), 2019 1.04 [0.81; 1.33]
KEYNOTE-042 (PDL1>20%), 2019 1.24 [0.92; 1.66]
KEYNOTE-042 (PDL1>50%), 2019 1.39 [0.99; 1.94]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.43]
1.18 [0.96 ; 1.45 ] CheckMate 026 (PDL1>5%), 2016, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, MYSTIC (D ; PDL1>25%), 2020 10 62% 5,394 moderate low objective responses (ORR) (extension)detailed results IMpower-110 (TC3 or IC3), 2020 1.68 [0.94; 3.01]
KEYNOTE-024 (PDL1>50%), 2016 1.89 [1.19; 3.02]
KEYNOTE-042 (PDL1>1%), 2019 1.03 [0.81; 1.32]
KEYNOTE-042 (PDL1>20%), 2019 1.21 [0.90; 1.62]
KEYNOTE-042 (PDL1>50%), 2019 1.35 [0.96; 1.88]
1.30 [1.06 ; 1.59 ] IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019 5 39% 3,201 moderate serious AE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.52 [0.27; 1.01]
MYSTIC (D ; PDL1>25%), 2020 0.42 [0.14; 1.22]
0.49 [0.28 ; 0.86 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 863 moderate not evaluable AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.39 [0.27; 0.55]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.41]
0.59 [0.26 ; 1.35 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, MYSTIC (D ; PDL1>25%), 2020 2 88% 863 moderate not evaluable AE leading to death (grade 5)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.39; 2.15]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.20; 2.86]
0.87 [0.42 ; 1.78 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 863 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.34 [0.19; 0.61]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.38; 1.46]
0.50 [0.23 ; 1.07 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, MYSTIC (D ; PDL1>25%), 2020 2 67% 863 moderate not evaluable SAE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.99 [0.68; 1.44]
MYSTIC (D ; PDL1>25%), 2020 1.22 [0.77; 1.94]
1.07 [0.80 ; 1.44 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 863 moderate not evaluable STRAE (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.93 [0.60; 1.46]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.50 [0.29; 0.85]
KEYNOTE-024 (PDL1>50%), 2016 1.05 [0.60; 1.82]
MYSTIC (D ; PDL1>25%), 2020 0.38 [0.18; 0.77]
0.68 [0.43 ; 1.07 ] CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; PDL1>25%), 2020 4 63% 1,697 moderate not evaluable STRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.82 [0.50; 1.33]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.55; 1.72]
0.88 [0.61 ; 1.27 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable TRAE (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.20 [0.12; 0.34]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.27 [0.18; 0.40]
KEYNOTE-024 (PDL1>50%), 2016 0.31 [0.16; 0.58]
KEYNOTE-042 (PDL1>1%), 2019 0.19 [0.14; 0.26]
MYSTIC (D ; PDL1>25%), 2020 0.21 [0.12; 0.38]
0.22 [0.18 ; 0.27 ] CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; PDL1>25%), 2020 5 0% 2,948 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.21 [0.14; 0.31]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.19 [0.12; 0.29]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.20; 0.51]
KEYNOTE-042 (PDL1>1%), 2019 0.30 [0.23; 0.39]
MYSTIC (D ; PDL1>25%), 2020 0.36 [0.22; 0.61]
0.26 [0.21 ; 0.33 ] CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; PDL1>25%), 2020 5 39% 2,948 moderate not evaluable TRAE leading to death (grade 5)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.03; 3.11]
KEYNOTE-042 (PDL1>1%), 2019 0.90 [0.42; 1.92]
MYSTIC (D ; PDL1>25%), 2020 0.95 [0.06; 15.32]
0.80 [0.40 ; 1.58 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; PDL1>25%), 2020 4 0% 2,418 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.70 [0.41; 1.20]
KEYNOTE-024 (PDL1>50%), 2016 0.64 [0.29; 1.44]
KEYNOTE-042 (PDL1>1%), 2019 0.95 [0.64; 1.39]
MYSTIC (D ; PDL1>25%), 2020 0.47 [0.21; 1.04]
0.77 [0.59 ; 1.01 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; PDL1>25%), 2020 4 0% 2,399 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.24 [0.64; 2.40]
KEYNOTE-024 (PDL1>50%), 2016 0.86 [0.32; 2.29]
KEYNOTE-042 (PDL1>1%), 2019 1.09 [0.71; 1.66]
1.09 [0.78 ; 1.53 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,085 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
3.88 [0.17 ; 86.15 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
0.18 [0.01 ; 2.28 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 14% 1,781 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.13]
KEYNOTE-024 (PDL1>50%), 2016 0.08 [0.02; 0.28]
KEYNOTE-042 (PDL1>1%), 2019 0.04 [0.02; 0.12]
0.05 [0.02 ; 0.10 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,085 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.97 [0.02 ; 48.81 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.12 [0.01; 2.31]
KEYNOTE-042 (PDL1>1%), 2019 0.29 [0.08; 1.05]
0.25 [0.08 ; 0.82 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,781 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
KEYNOTE-024 (PDL1>50%), 2016 0.49 [0.02; 14.58]
0.98 [0.09 ; 10.85 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable Colitis TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-024 (PDL1>50%), 2016 3.93 [0.18; 87.97]
KEYNOTE-042 (PDL1>1%), 2019 3.89 [0.43; 34.87]
3.85 [0.82 ; 18.18 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,104 moderate not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.98 [0.10 ; 9.40 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,085 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.24 [0.03; 2.19]
KEYNOTE-024 (PDL1>50%), 2016 0.12 [0.01; 2.27]
KEYNOTE-042 (PDL1>1%), 2019 0.53 [0.18; 1.60]
0.40 [0.16 ; 1.01 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,085 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
1.95 [0.07 ; 58.69 ] KEYNOTE-024 (PDL1>50%), 2016 1 0% 304 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.59 [0.14; 2.48]
KEYNOTE-024 (PDL1>50%), 2016 3.00 [0.60; 15.11]
KEYNOTE-042 (PDL1>1%), 2019 4.87 [0.57; 41.77]
1.77 [0.48 ; 6.46 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 42% 2,085 moderate not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.98 [0.06 ; 15.72 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.20 [0.06; 0.71]
KEYNOTE-024 (PDL1>50%), 2016 0.38 [0.07; 2.00]
KEYNOTE-042 (PDL1>1%), 2019 0.36 [0.09; 1.36]
0.29 [0.13 ; 0.64 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,085 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.19 [0.36; 3.94]
1.19 [0.36 ; 3.94 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 11.47 [1.48; 88.87]
KEYNOTE-042 (PDL1>1%), 2019 13.68 [0.77; 241.54]
12.17 [2.30 ; 64.46 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,800 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.26 [0.15 ; 10.81 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,104 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
3.62 [0.38 ; 34.25 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.19 [0.18 ; 7.84 ] CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 4 0% 2,634 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.35; 10.63]
1.94 [0.35 ; 10.63 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 3.51 [0.72; 17.07]
KEYNOTE-042 (PDL1>1%), 2019 1.75 [0.58; 5.26]
2.20 [0.89 ; 5.42 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,781 moderate not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.16 [0.02; 1.33]
0.31 [0.06 ; 1.66 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,104 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.05 [0.00; 0.92]
KEYNOTE-042 (PDL1>1%), 2019 0.05 [0.00; 0.82]
0.05 [0.01 ; 0.38 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,781 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
1.97 [0.07 ; 59.09 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
0.98 [0.02 ; 49.83 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.06 ; 57.80 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.06 ; 57.80 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.97 [0.02 ; 49.41 ] KEYNOTE-024 (PDL1>50%), 2016 1 0% 304 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.19 [0.02; 1.67]
KEYNOTE-024 (PDL1>50%), 2016 0.16 [0.01; 3.21]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
0.14 [0.03 ; 0.62 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,085 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.18 ; 21.52 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.25]
KEYNOTE-024 (PDL1>50%), 2016 0.02 [0.00; 0.35]
KEYNOTE-042 (PDL1>1%), 2019 0.02 [0.00; 0.14]
0.02 [0.00 ; 0.08 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,085 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
1.44 [0.11 ; 18.87 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 1.76]
0.22 [0.02 ; 2.27 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,781 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
0.98 [0.02 ; 49.83 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.08 [0.00; 1.43]
0.08 [0.00 ; 1.43 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-024 (PDL1>50%), 2016 3.97 [0.44; 35.97]
KEYNOTE-042 (PDL1>1%), 2019 20.97 [2.81; 156.36]
8.21 [2.15 ; 31.32 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,104 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
1.52 [0.15 ; 15.00 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,781 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.66 [0.05 ; 8.61 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.98 [0.18; 21.94]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
2.01 [0.55 ; 7.36 ] CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,330 moderate not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
1.97 [0.07 ; 59.09 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 12.07 [0.67; 217.19]
12.07 [0.67 ; 217.19 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 12.12 [0.67; 218.98]
KEYNOTE-042 (PDL1>1%), 2019 10.81 [1.39; 83.96]
11.23 [2.11 ; 59.83 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 5.00 [0.58; 43.09]
5.00 [0.58 ; 43.09 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
KEYNOTE-024 (PDL1>50%), 2016 0.24 [0.01; 5.39]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.44 [0.06 ; 3.17 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,085 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.04 [0.01; 0.31]
KEYNOTE-024 (PDL1>50%), 2016 0.06 [0.00; 1.02]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 0.75]
0.06 [0.02 ; 0.22 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,085 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.97 [0.06 ; 15.56 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.10 [0.01; 1.78]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.06; 15.71]
KEYNOTE-042 (PDL1>1%), 2019 0.24 [0.01; 5.36]
0.30 [0.05 ; 1.60 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,085 moderate not evaluable Anaemia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.08 [0.03; 0.20]
0.08 [0.03 ; 0.20 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Asthenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.36 [0.07; 1.89]
0.36 [0.07 ; 1.89 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Constipation AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
1.38 [0.23 ; 8.34 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Cough AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.84 [0.06; 55.14]
1.84 [0.06 ; 55.14 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
3.70 [0.17 ; 82.36 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.01; 5.09]
0.23 [0.01 ; 5.09 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
3.70 [0.17 ; 82.36 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Fatigue AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.30 [0.06; 1.51]
0.30 [0.06 ; 1.51 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.05 [0.00; 0.86]
0.05 [0.00 ; 0.86 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Hypertension AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.61 [0.10; 3.68]
0.61 [0.10 ; 3.68 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Increase AST AE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 7.05 [0.86; 57.74]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17]
5.76 [1.28 ; 25.94 ] CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020 2 0% 1,079 moderate not evaluable Increased ALT AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17]
4.66 [0.54 ; 40.17 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.03; 2.05]
0.23 [0.03 ; 2.05 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Nausea AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.18 [0.02; 1.56]
0.18 [0.02 ; 1.56 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Neutropenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.03 [0.01; 0.14]
0.03 [0.01 ; 0.14 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Pancytopenia (AE grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.04; 5.08]
0.46 [0.04 ; 5.08 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Pneumonia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.71 [0.26; 1.93]
0.71 [0.26 ; 1.93 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73]
0.46 [0.02 ; 13.73 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Sepsis AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.04; 5.08]
0.46 [0.04 ; 5.08 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.05 [0.01; 0.34]
0.05 [0.01 ; 0.34 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Vomiting AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.04; 5.08]
0.46 [0.04 ; 5.08 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-21 03:29 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 171
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563